ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-836-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.61 billion
Profitability
Miscellaneous
Employees7,240
Next Earnings Date1/30/2020 (Confirmed)
OptionableOptionable
ResMed (NYSE:RMD) Frequently Asked Questions
What is ResMed's stock symbol?
ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."
How often does ResMed pay dividends? What is the dividend yield for ResMed?
ResMed announced a quarterly dividend on Thursday, October 24th. Investors of record on Thursday, November 7th will be paid a dividend of $0.39 per share on Thursday, December 12th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Wednesday, November 6th. View ResMed's Dividend History.
How were ResMed's earnings last quarter?
ResMed Inc. (NYSE:RMD) released its quarterly earnings results on Thursday, October, 24th. The medical equipment provider reported $0.93 earnings per share for the quarter, beating analysts' consensus estimates of $0.87 by $0.06. The medical equipment provider earned $681.06 million during the quarter, compared to analysts' expectations of $660.87 million. ResMed had a return on equity of 26.72% and a net margin of 15.52%. The firm's revenue was up 15.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.81 earnings per share. View ResMed's Earnings History.
When is ResMed's next earnings date?
How can I listen to ResMed's earnings call?
ResMed will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for RMD?
8 brokerages have issued 12 month price targets for ResMed's shares. Their forecasts range from $95.00 to $140.00. On average, they anticipate ResMed's stock price to reach $118.33 in the next year. This suggests that the stock has a possible downside of 26.3%. View Analyst Price Targets for ResMed.
What is the consensus analysts' recommendation for ResMed?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ResMed.
Has ResMed been receiving favorable news coverage?
News stories about RMD stock have been trending negative on Saturday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ResMed earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for ResMed.
Who are some of ResMed's key competitors?
Some companies that are related to ResMed include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).
What other stocks do shareholders of ResMed own?
Who are ResMed's key executives?
ResMed's management team includes the folowing people:
- Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
- Mr. Robert A. Douglas, Pres & COO (Age 59)
- Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
- Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
- Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)
Who are ResMed's major shareholders?
ResMed's stock is owned by a number of of retail and institutional investors. Top institutional investors include Welch & Forbes LLC (0.21%), Capital Investment Services of America Inc. (0.11%), Gateway Investment Advisers LLC (0.08%), Nisa Investment Advisors LLC (0.07%), Tandem Investment Advisors Inc. (0.05%) and State of Alaska Department of Revenue (0.04%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Institutional Ownership Trends for ResMed.
Which institutional investors are selling ResMed stock?
RMD stock was sold by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Gateway Investment Advisers LLC, Welch & Forbes LLC, IFM Investors Pty Ltd, West Coast Financial LLC, Capital Investment Services of America Inc. and Coastline Trust Co. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.
Which institutional investors are buying ResMed stock?
RMD stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Johanson Financial Advisors Inc., State of Alaska Department of Revenue, Tuttle Tactical Management, Nisa Investment Advisors LLC, Perigon Wealth Management LLC, DNB Asset Management AS and Boston Trust Walden Corp. View Insider Buying and Selling for ResMed.
How do I buy shares of ResMed?
Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ResMed's stock price today?
One share of RMD stock can currently be purchased for approximately $160.57.
How big of a company is ResMed?
ResMed has a market capitalization of $23.09 billion and generates $2.61 billion in revenue each year. The medical equipment provider earns $404.59 million in net income (profit) each year or $3.64 on an earnings per share basis. ResMed employs 7,240 workers across the globe.View Additional Information About ResMed.
What is ResMed's official website?
How can I contact ResMed?
ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]
MarketBeat Community Rating for ResMed (NYSE RMD)
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
